On November 20, Beam Therapeutics, Inc. rose 5.21% in Regular Trading, trading at $21.64 per share, with turnover of $11.4496 million.
The move coincided with continued market digestion of positive progress for the company’s sickle cell disease candidate risto-cel, which remained the main catalyst behind recent share-price volatility.
Background context shows the BEACON 1/2 trial met primary efficacy and safety endpoints and achieved all secondary endpoints, while the company plans to submit a BLA to the FDA before year-end. At the same time, Beam Therapeutics, Inc. previously reported a quarterly loss of $1.28 per share, wider than the $1.15 loss expected, and market revenue expectations have turned more conservative. Even so, the clinical milestone has continued to support investor attention on the commercialization potential of its base-editing platform.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments